These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 25113814)

  • 1. Effect of local heating on postprandial blood glucose excursions using the InsuPad device: results of an outpatient crossover study.
    Hermanns N; Bitton G; Reimer A; Krichbaum M; Kulzer B; Haak T
    J Diabetes Sci Technol; 2014 Nov; 8(6):1126-32. PubMed ID: 25113814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes: Injection Site Warming to Improve Glycemic Control.
    Raz I; Bitton G; Feldman D; Alon T; Pfutzner A; Tamborlane WV
    J Diabetes Sci Technol; 2015 May; 9(3):639-43. PubMed ID: 25883166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical performance of a device that applies local heat to the insulin infusion site: a crossover study.
    Freckmann G; Pleus S; Westhoff A; Krinelke LG; Buhr A; Jendrike N; Haug C
    J Diabetes Sci Technol; 2012 Mar; 6(2):320-7. PubMed ID: 22538141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In children and young people with type 1 diabetes using Pump therapy, an additional 40% of the insulin dose for a high-fat, high-protein breakfast improves postprandial glycaemic excursions: A cross-over trial.
    Smith TA; Smart CE; Fuery MEJ; Howley PP; Knight BA; Harris M; King BR
    Diabet Med; 2021 Jul; 38(7):e14511. PubMed ID: 33405297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effect of insulin glulisine to insulin aspart on breakfast postprandial blood glucose levels in children with type 1 diabetes mellitus on multiple daily injections.
    Cemeroglu AP; Kleis L; Wood A; Parkes C; Wood MA; Davis AT
    Endocr Pract; 2013; 19(4):614-9. PubMed ID: 23425652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved insulin absorption by means of standardized injection site modulation results in a safer and more efficient prandial insulin treatment. A review of the existing clinical data.
    Pfützner A; Raz I; Bitton G; Klonoff D; Nagar R; Hermanns N; Haak T
    J Diabetes Sci Technol; 2015 Jan; 9(1):116-22. PubMed ID: 25352633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of thrice daily 'high' vs. 'medium' premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes.
    Ejskjaer N; Rasmussen M; Kamp N; Lindholm A; Christiansen JS
    Diabetes Obes Metab; 2003 Nov; 5(6):438-45. PubMed ID: 14617230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus.
    McSorley PT; Bell PM; Jacobsen LV; Kristensen A; Lindholm A
    Clin Ther; 2002 Apr; 24(4):530-9. PubMed ID: 12017398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with novel galactomannan derivative reduces 2-hour postprandial glucose excursions in individuals with type 2 diabetes treated with oral medications and/or insulin.
    Trask LE; Chaidarun SS; Platt D; Parkin CG
    J Diabetes Sci Technol; 2014 Sep; 8(5):1018-22. PubMed ID: 25172878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humalog Mix25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus.
    Herz M; Arora V; Campaigne BN; Scholtz HE; Potgieter MA; Mollentze W
    S Afr Med J; 2003 Mar; 93(3):219-23. PubMed ID: 12768948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Closed-Loop Control of Postprandial Glycemia Using an Insulin-on-Board Limitation Through Continuous Action on Glucose Target.
    Rossetti P; Quirós C; Moscardó V; Comas A; Giménez M; Ampudia-Blasco FJ; León F; Montaser E; Conget I; Bondia J; Vehí J
    Diabetes Technol Ther; 2017 Jun; 19(6):355-362. PubMed ID: 28459603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Barmer study: impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus.
    Pfützner A; Hermanns N; Funke K; Forst T; Behnke T; Bitton G; Nagar R; Raz I; Haak T
    Curr Med Res Opin; 2014 May; 30(5):753-60. PubMed ID: 24392996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination.
    Ono Y; Kamoshima H; Nakamura A; Nomoto H
    Expert Opin Pharmacother; 2014 Sep; 15(13):1785-95. PubMed ID: 25046055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of moderate exercise for 30 min at 30 min versus 60 min after dinner on glycemic control in patients with type 2 diabetes: a randomized, crossover, self-controlled study].
    Li Z; Hu Y; Ma J
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Sep; 38(10):1165-1170. PubMed ID: 30377118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes.
    Kipnes M; Dandona P; Tripathy D; Still JG; Kosutic G
    Diabetes Care; 2003 Feb; 26(2):421-6. PubMed ID: 12547873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
    Levetan C; Want LL; Weyer C; Strobel SA; Crean J; Wang Y; Maggs DG; Kolterman OG; Chandran M; Mudaliar SR; Henry RR
    Diabetes Care; 2003 Jan; 26(1):1-8. PubMed ID: 12502651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
    Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
    Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.
    Home PD; Lindholm A; Hylleberg B; Round P
    Diabetes Care; 1998 Nov; 21(11):1904-9. PubMed ID: 9802741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.